175 related articles for article (PubMed ID: 21481181)
1. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Rupin A; Marx I; Vallez MO; Mennecier P; Gloanec P; De Nanteuil G; Verbeuren TJ
J Thromb Haemost; 2011 Jul; 9(7):1375-82. PubMed ID: 21481181
[TBL] [Abstract][Full Text] [Related]
2. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
7. New options with dabigatran etexilate in anticoagulant therapy.
Maegdefessel L; Spin JM; Azuma J; Tsao PS
Vasc Health Risk Manag; 2010 May; 6():339-49. PubMed ID: 20531953
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
9. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Wong PC; Crain EJ; Watson CA; Xin B
J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
[TBL] [Abstract][Full Text] [Related]
11. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Aug; 98(2):333-8. PubMed ID: 17721615
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Stangier J
Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
14. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Blommel ML; Blommel AL
Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
[TBL] [Abstract][Full Text] [Related]
16. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]